These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 16010589

  • 1. Structure-activity study of the interaction of bioreductive benzoquinone alkylating agents with DNA topoisomerase II.
    Hasinoff BB, Wu X, Begleiter A, Guziec LJ, Guziec F, Giorgianni A, Yang S, Jiang Y, Yalowich JC.
    Cancer Chemother Pharmacol; 2006 Jan; 57(2):221-33. PubMed ID: 16010589
    [Abstract] [Full Text] [Related]

  • 2. Structure-activity study with bioreductive benzoquinone alkylating agents: effects on DT-diaphorase-mediated DNA crosslink and strand break formation in relation to mechanisms of cytotoxicity.
    Fourie J, Guziec F, Guziec L, Monterrosa C, Fiterman DJ, Begleiter A.
    Cancer Chemother Pharmacol; 2004 Mar; 53(3):191-203. PubMed ID: 14614574
    [Abstract] [Full Text] [Related]

  • 3. Topoisomerase II-mediated DNA cleavage activity and irreversibility of cleavable complex formation induced by DNA intercalator with alkylating capability.
    Kong XB, Rubin L, Chen LI, Ciszewska G, Watanabe KA, Tong WP, Sirotnak FM, Chou TC.
    Mol Pharmacol; 1992 Feb; 41(2):237-44. PubMed ID: 1311406
    [Abstract] [Full Text] [Related]

  • 4. The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase.
    Fourie J, Oleschuk CJ, Guziec F, Guziec L, Fiterman DJ, Monterrosa C, Begleiter A.
    Cancer Chemother Pharmacol; 2002 Feb; 49(2):101-10. PubMed ID: 11862423
    [Abstract] [Full Text] [Related]

  • 5. Quantitative and qualitative aspects of topoisomerase I and II alpha and beta in untreated and platinum/cyclophosphamide treated malignant ovarian tumors.
    van der Zee AG, de Jong S, Keith WN, Hollema H, Boonstra H, de Vries EG.
    Cancer Res; 1994 Feb 01; 54(3):749-55. PubMed ID: 8306337
    [Abstract] [Full Text] [Related]

  • 6. Thiol-modulated mechanisms of the cytotoxicity of thimerosal and inhibition of DNA topoisomerase II alpha.
    Wu X, Liang H, O'Hara KA, Yalowich JC, Hasinoff BB.
    Chem Res Toxicol; 2008 Feb 01; 21(2):483-93. PubMed ID: 18197631
    [Abstract] [Full Text] [Related]

  • 7. Induction of apoptosis by plumbagin through reactive oxygen species-mediated inhibition of topoisomerase II.
    Kawiak A, Piosik J, Stasilojc G, Gwizdek-Wisniewska A, Marczak L, Stobiecki M, Bigda J, Lojkowska E.
    Toxicol Appl Pharmacol; 2007 Sep 15; 223(3):267-76. PubMed ID: 17618663
    [Abstract] [Full Text] [Related]

  • 8. Topoisomerase I/II selectivity among derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA).
    Bridewell DJ, Finlay GJ, Baguley BC.
    Anticancer Drug Des; 2001 Dec 15; 16(6):317-24. PubMed ID: 12375884
    [Abstract] [Full Text] [Related]

  • 9. Activity of quinone alkylating agents in quinone-resistant cells.
    Begleiter A, Leith MK.
    Cancer Res; 1990 May 15; 50(10):2872-6. PubMed ID: 1692249
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of eukaryotic DNA topoisomerase I and II activities by indoloquinolinedione derivatives.
    Riou JF, Helissey P, Grondard L, Giorgi-Renault S.
    Mol Pharmacol; 1991 Nov 15; 40(5):699-706. PubMed ID: 1658605
    [Abstract] [Full Text] [Related]

  • 11. Structure-activity studies with cytotoxic anthrapyrazoles.
    Begleiter A, Lin D, Larson KK, Lang J, Wu X, Cabral T, Taylor H, Guziec LJ, Kerr PD, Hasinoff BB, Guziec FS.
    Oncol Rep; 2006 Jun 15; 15(6):1575-80. PubMed ID: 16685398
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Curcumin induces high levels of topoisomerase I- and II-DNA complexes in K562 leukemia cells.
    López-Lázaro M, Willmore E, Jobson A, Gilroy KL, Curtis H, Padget K, Austin CA.
    J Nat Prod; 2007 Dec 15; 70(12):1884-8. PubMed ID: 18076140
    [Abstract] [Full Text] [Related]

  • 16. Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II.
    Adjei AA, Charron M, Rowinsky EK, Svingen PA, Miller J, Reid JM, Sebolt-Leopold J, Ames MM, Kaufmann SH.
    Clin Cancer Res; 1998 Mar 15; 4(3):683-91. PubMed ID: 9533538
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Suramin inhibits the phosphorylation and catalytic activity of DNA topoisomerase II in human lung cancer cells.
    Funayama Y, Nishio K, Takeda Y, Kubota N, Ohira T, Ohmori T, Ohta S, Ogasawara H, Hasegawa S, Saijo N.
    Anticancer Res; 1993 Mar 15; 13(6A):1981-8. PubMed ID: 8297104
    [Abstract] [Full Text] [Related]

  • 20. Quinone-induced DNA damage and its relationship to antitumor activity in L5178Y lymphoblasts.
    Begleiter A, Blair GW.
    Cancer Res; 1984 Jan 15; 44(1):78-82. PubMed ID: 6537800
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.